Research Use Only. KIRhub outputs are computational research artifacts. They are not validated for clinical decision-making, diagnosis, or treatment.

← Cohorts · breast-umap@18

SRR25617861

— · A

f0d9a344-4b79-57c8-a3df-fc2d993f0329

Score in workbench →

Clinical attributes

From the source cohort, normalized into canonical keys plus the project's native columns.

cancer_type
—
cancer_type_detailed
—
subtype
A
subtype
A

GSVA pathway preview (50 Hallmark scores)

MeasuredDerivedReference

Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.

Top 10 elevated

  • INTERFERON_ALPHA_RESPONSE+0.430
  • INFLAMMATORY_RESPONSE+0.420
  • INTERFERON_GAMMA_RESPONSE+0.400
  • PANCREAS_BETA_CELLS+0.400
  • TNFA_SIGNALING_VIA_NFKB+0.380
  • KRAS_SIGNALING_DN+0.360
  • COMPLEMENT+0.280
  • COAGULATION+0.240
  • IL6_JAK_STAT3_SIGNALING+0.230
  • IL2_STAT5_SIGNALING+0.180

Top 10 suppressed

  • G2M_CHECKPOINT-0.500
  • E2F_TARGETS-0.480
  • MYC_TARGETS_V1-0.450
  • MITOTIC_SPINDLE-0.430
  • NOTCH_SIGNALING-0.410
  • TGF_BETA_SIGNALING-0.380
  • MYC_TARGETS_V2-0.360
  • PROTEIN_SECRETION-0.340
  • WNT_BETA_CATENIN_SIGNALING-0.340
  • DNA_REPAIR-0.330

Patient twins — nearest pathway neighbors

MeasuredDerived

10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.

8 twins match this tumor's tissue · 2 come from a different tissue of origin

#SampleCancer typeSubtypecos similarity
138ac1da2-32a1-4530-a553-e5adff884b4f
melanoma-umap@29
——0.873
2SRR25617934
breast-umap@18
—A0.845
3SRR1331511
brain-umap@2
GTEX—0.842
4SRR25617853
breast-umap@18
—D0.841
5MBCProject_0026_T2_RNA
breast-umap@18
—E0.839
6TCGA-55-7728-01A-11R-2187-07
lung-landscapes@6
—cohortA10.837
7SRR8518255
breast-umap@18
—D0.836
8MDT-AP-2296
medullo-epn-umap@date-based
MedMedulloblastoma0.824
9TCGA-86-A456-01A-11R-A24H-07
lung-landscapes@6
—cohortA10.822
103d89c16f-8045-4861-a82c-9f4624292284
melanoma-umap@29
——0.820

Per-pathway drug coverage

ModeledCalibratedDerived

For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.

0 of 20 elevated pathways have at least one drug that meaningfully reverses them.

Pathway (elevated)tumor scoreBest drugreversal magnitude
INTERFERON_ALPHA_RESPONSE0.430Inavolisib— uncovered
INFLAMMATORY_RESPONSE0.420Idelalisib— uncovered
INTERFERON_GAMMA_RESPONSE0.400Idelalisib— uncovered
PANCREAS_BETA_CELLS0.400Cobimetinib— uncovered
TNFA_SIGNALING_VIA_NFKB0.380Inavolisib— uncovered
KRAS_SIGNALING_DN0.360Remibrutinib— uncovered
COMPLEMENT0.280Inavolisib— uncovered
COAGULATION0.240Binimetinib— uncovered
IL6_JAK_STAT3_SIGNALING0.230Inavolisib— uncovered
IL2_STAT5_SIGNALING0.180Idelalisib— uncovered
ANGIOGENESIS0.140Remibrutinib— uncovered
HYPOXIA0.130Idelalisib— uncovered
SPERMATOGENESIS0.130Inavolisib— uncovered
KRAS_SIGNALING_UP0.110Inavolisib— uncovered
CHOLESTEROL_HOMEOSTASIS0.080Remibrutinib— uncovered
ALLOGRAFT_REJECTION0.070Idelalisib— uncovered
XENOBIOTIC_METABOLISM0.060Inavolisib— uncovered
MYOGENESIS0.050Inavolisib— uncovered
REACTIVE_OXYGEN_SPECIES_PATHWAY0.050Inavolisib— uncovered
BILE_ACID_METABOLISM0.040Inavolisib— uncovered